For: | Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i39/4372.htm |
Number | Citing Articles |
1 |
Igor G. Bakulin, Maria I. Skalinskaya, Igor V. Maev, Ekaterina V. Skazyvaeva, Mariia S. Zhuravleva, Larisa B. Gaikovaya, Natalia V. Bakulina, Aleksei I. Ermakov, Ekaterina S. Alekseenko, Kristina N. Ivanova, Mikhail V. Solovev. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Terapevticheskii arkhiv 2021; 93(8): 841 doi: 10.26442/00403660.2021.08.200982
|
2 |
Carla Caldas Marques, Morgana T. Castelo-Branco, Rodrigo G. Pacheco, Fernanda Buongusto, Alyson do Rosário, Alberto Schanaider, Robson Coutinho-Silva, Heitor S.P. de Souza. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014; 1842(1): 65 doi: 10.1016/j.bbadis.2013.10.012
|
3 |
Olof Modén, Bengt Mannervik. Redox and Cancer Part A. Advances in Cancer Research 2014; 122: 199 doi: 10.1016/B978-0-12-420117-0.00006-2
|
4 |
Gordon W Moran, Marie-France Dubeau, Gilaad G Kaplan, Hong Yang, Bertus Eksteen, Subrata Ghosh, Remo Panaccione. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World Journal of Gastroenterology 2015; 21(25): 7795-7804 doi: 10.3748/wjg.v21.i25.7795
|